22-May-2025Today's Market Indicators

Glenmark Pharmaceuticals Ltd

  • Industry: Pharmaceuticals Indian Bulk Drugs & Formln
  • Market Cap (₹ Cr.): 40629.86
  • CURRENT PRICE (₹)
      1,431.10  -8.65(-0.60 %)
    22-May-2025 12:00:00 AM
    Volume 4,441
  • Day's Open (₹)
    1,425.05
  • Day's High (₹)
    1,439.00
  • Day's Low (₹)
    1,418.05
  • Prev.Close (₹)
    1,439.75
JavaScript chart by amCharts 3.21.1409:0109:2909:5310:1710:4111:0511:2911:5312:1712:4101:0501:2901:5302:1702:4103:0503:291,4101,4201,4301,440

52 Week High/Low 1,830.05 / 998.95

-0.25%

Stock Trivia

19-May-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
19-May-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
12-May-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Tra
07-May-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Dis
05-May-25
Ichnos Glenmark Innovation receives USFDA fast track designation for
05-May-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
29-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - New
28-Apr-25
Glenmark Pharmaceuticals Ltd - Format of the Annual Disclosure to be
28-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - New
28-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Sha
25-Apr-25
Glenmark Pharmaceuticals Ltd - Shareholder Meeting / Postal Ballot-Ou
16-Apr-25
Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspa
07-Apr-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
07-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - App
07-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ces
07-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - App
07-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ces
01-Apr-25
Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Inject
01-Apr-25
Glenmark launches Vancomycin Hydrochloride for injection USP in the U
01-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Upd
01-Apr-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
28-Mar-25
Glenmark Pharmaceuticals Ltd - Disclosure Under Regulation 30 Of The
27-Mar-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
27-Mar-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Cop
27-Mar-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Sha
21-Mar-25
Stock Alert: Hindustan Unilever, Hindalco Inds, Glenmark Pharma, Asho
21-Mar-25
Glenmark Pharma gains as arm gets USFDA nod for Olopatadine Ophthalmi
20-Mar-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
12-Mar-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
12-Mar-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
12-Mar-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
10-Mar-25
Glenmark launches Polyethylene Glycol 3350, Powder for Solution, 17 g
10-Mar-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
10-Mar-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
05-Mar-25
Glenmark Pharmaceuticals Ltd soars 3.49%, rises for third straight se
03-Mar-25
Glenmark announces acquisition and launch of Acetylcysteine Injection
28-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
27-Feb-25
Glenmark Pharma launches Epinephrine Injection USP, 10 mg/10 mL Multi
27-Feb-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
27-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
27-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
24-Feb-25
Glenmark Pharma gains on settling U.S. antitrust lawsuits for $7 mill
20-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
19-Feb-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
19-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
17-Feb-25
Glenmark Pharma gains on reporting turnaround PAT of Rs 348 crore in
17-Feb-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
17-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
17-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Cha
17-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
15-Feb-25
Glenmark Pharmaceuticals reports consolidated net profit of Rs 347.96
14-Feb-25
Glenmark Pharma's US arm launches Latanoprost's bioequivalent solutio
14-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
14-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
12-Feb-25
Barometers trade with modest cuts; Oil & gas shares extent losses for
12-Feb-25
Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR
12-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
10-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
10-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
08-Feb-25
Glenmark Pharmaceuticals Ltd - Intimation Under Regulation 30 Of SEBI
07-Feb-25
Glenmark Pharmaceuticals Ltd - Intimation Under Regulation 30 Of SEBI
05-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
05-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Ana
04-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Boa
03-Feb-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Tra
21-Jan-25
Glenmark Pharmaceuticals launches Phytonadione Injectable Emulsion US
21-Jan-25
Glenmark Pharma edges higher after US launch of coagulation disorder
21-Jan-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
09-Jan-25
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Oth
16-Dec-24
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
16-Dec-24
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
10-Dec-24
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre
27-Nov-24
Glenmark Pharma arm launches Travoprost Ophthalmic Solution in U.S ma
27-Nov-24
Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Pre

Score Board

Dec 24
(Latest Qtr)
FY24
(Latest Financial Year)
Market Cap (₹ Cr)45399.8427019.52
Sales(₹ Cr)2208.847891.12
(% Change)-15%-4%
Net Profit(₹ Cr)413.805167.29
(% Change)-30%327%
Per Share Data
Earnings (₹)14.66183.11
Book Value (₹)0.00814.01
Cash (₹)974.28-17.56
Dividend (₹)0.002.50

Key Ratios

Important Finanical ratios for

FY24FY23FY22FY21FY20
EPS183.1142.8470.8058.4648.00
Book Value per share814.01633.57593.21524.84468.73
Dividend per share2.502.502.502.502.50

Financial Health

Profit & Loss

Dec 2024Sep 2024Jun 2024Mar 2024
Gross Sales 2208.842594.892296.882077.13
Other Operating Income 42.4441.2132.6671.09
Other Income  129.1983.0855.655933.18
Total Income 2380.472719.182385.198081.41
Total Expenditure  1757.351857.471698.441650.78
PBIDT 623.12861.70686.756430.63
Interest  8.4611.8015.3583.39
PBDT 614.65849.91671.406347.25
Depreciation 55.1654.8553.0952.40
Tax 95.26138.46107.981055.38
Fringe Benefit Tax 0.000.000.000.00
Deferred Tax 50.4361.5456.60625.77
Reported Profit After Tax 413.80595.06453.734613.70
Extra-ordinary Items  0.000.000.003772.34
Adjusted Profit After Extra-ordinary item 413.80595.06453.73841.36
     
EPS (Unit Curr.) 14.6621.0916.08163.50
EPS (Adj) (Unit Curr.) 14.6621.0916.08163.50
Calculated EPS (Unit Curr.) 14.6621.0916.08163.50
Calculated EPS (Adj) (Unit Curr.) 14.6621.0916.08163.50
Calculated EPS (Ann.) (Unit Curr.) 58.6684.3564.32653.98
Calculated EPS (Adj) (Ann.) (Unit Curr.) 58.6684.3564.32653.98
Book Value (Unit Curr.) 0.000.000.000.00
Dividend (%) 0.000.000.000.00
Equity 28.2228.2228.2228.22
Reserve & Surplus 0.000.000.000.00
Face Value 1.001.001.001.00
     
Public Shareholding (No. Of Shares) 0.000.000.000.00
Public Shareholding (% in Equity) 0.000.000.000.00
     
Pledged/Encumbered - No. of Shares 0.000.000.000.00
Pledged/Encumbered - % in Total Promoters Holding 0.000.000.000.00
Pledged/Encumbered - % in Total Equity 0.000.000.000.00
     
Non Encumbered - No. of Shares 0.000.000.000.00
Non Encumbered - % in Total Promoters Holding 0.000.000.000.00
Non Encumbered - % in Total Equity 0.000.000.000.00
     
PBIDTM(%) 28.2133.2129.90309.59
PBDTM(%) 27.8332.7529.23305.58
PATM(%) 18.7322.9319.75222.12
Dividend Per Share(Rs) 0.000.000.000.00
Diluted EPS 14.6621.0916.08163.50

Balance Sheet

FY24FY23FY22FY21FY20
SOURCES OF FUNDS :     
Share Capital 28.2228.2228.2228.2228.22
Reserves Total 22942.4017849.2516710.3714781.2913198.05
Equity Share Warrants0.000.000.000.000.00
Equity Application Money0.000.000.000.000.00
Total Shareholders Funds22970.6217877.4716738.5914809.5113226.27
Secured Loans 0.000.000.000.000.00
Unsecured Loans 707.293221.223737.703703.993573.76
Total Debt707.293221.223737.703703.993573.76
Other Liabilities131.94372.58121.32136.61205.65
Total Liabilities23809.8521471.2720597.6118650.1117005.68
APPLICATION OF FUNDS :     
Gross Block 3392.753183.653026.282848.562595.06
Less : Accumulated Depreciation 1636.501437.701273.951126.07983.11
Less:Impairment of Assets0.000.000.000.000.00
Net Block 1756.251745.951752.331722.491611.95
Lease Adjustment0.000.000.000.000.00
Capital Work in Progress197.67172.34109.04131.40200.01
Producing Properties0.000.000.000.000.00
Investments 12964.7910332.718559.396989.954713.93
Current Assets, Loans & Advances     
Inventories 1142.691090.21951.66762.39837.50
Sundry Debtors 2484.472505.662678.322488.751835.24
Cash and Bank Balance129.1593.7929.6315.7988.26
Loans and Advances 925.17696.82743.311642.201662.89
Total Current Assets4681.484386.484402.934909.124423.89
Less : Current Liabilities and Provisions     
Current Liabilities 3249.792952.142168.391834.311827.48
Provisions 354.74162.52148.49133.11118.45
Total Current Liabilities & Provisions3604.543114.662316.881967.411945.92
Net Current Assets1076.941271.822086.052941.712477.97
Miscellaneous Expenses not written off 0.000.000.000.000.00
Deferred Tax Assets475.611160.251137.471118.721081.34
Deferred Tax Liability309.77213.50214.20265.43276.60
Net Deferred Tax165.84946.75923.27853.29804.74
Other Assets7648.377001.707167.546011.277197.08
Total Assets23809.8521471.2620597.6218650.1117005.68
Contingent Liabilities2658.493443.303325.063730.174430.59

Cash Flow

FY24FY23FY22FY21FY20
Net Cash from Operating Activities-495.451474.061216.071243.421579.12
Net Cash Used In Investing Activities3197.17-431.52-897.02-1235.19-1607.41
Net Cash Used In Financing Activities-2666.45-978.5-305.12-80.79-139.42
Net Inc/Dec In Cash And Cash Equivalents35.2764.0513.93-72.57-167.71
Cash And Cash Equivalents At End Of The Year127.9692.728.6514.7287.29

Peer Comparison

Performance of Glenmark Pharmaceuticals Ltd Compared to its peers in Pharmaceuticals Indian Bulk Drugs & Formln

Company Market Cap   help

Market capitalization (market cap) is the market value of a publicly traded company's outstanding shares. Market capitalization is equal to the share price multiplied by the number of shares outstanding.

(₹ in Cr.)
P/E  help

The price-to-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings (EPS).

(X)
P/B  help

The PBV ratio is the market price per share divided by the book value per share. For example, a stock with a PBV ratio of 2 means that we pay Rs 2 for every Rs. 1 of book value. The higher the PBV, the more expensive the stock. Most companies have a PBV greater than one.

(X)
EV/EBITDA  help

Enterprise value/EBITDA is a popular valuation multiple used in the finance industry to measure the value of a company. It is the most widely used valuation multiple based on enterprise value and is often used in conjunction with, or as an alternative to, the P/E ratio to determine the fair market value of a company.

ROCE  help

Return on capital employed is an accounting ratio used in finance, valuation, and accounting. It is a useful measure for comparing the relative profitability of companies after taking into account the amount of capital used.

( % )
Dividend  help

A dividend is a payment made by a corporation to its shareholders, usually as a distribution of profits. When a corporation earns a profit or surplus, the corporation is able to re-invest the profit in the business and pay a proportion of the profit as a dividend to shareholders.

( % )
Debit to Equity  help

The debt-to-equity ratio is a financial ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. Closely related to leveraging, the ratio is also known as risk, gearing or leverage.

(Ratio(D / E) )
Glenmark Pharmaceuticals Ltd4038617.531.184.659.750.170.10
Sun Pharmaceutical Industries Ltd412686131.0016.4170.4912.220.780.40
Divis Laboratories Ltd17357178.586.7551.1116.270.460.00
Cipla Ltd11850524.064.3116.9420.101.090.00
Torrent Pharmaceuticals Ltd10873857.0712.8931.7720.401.000.60